特发性肺纤维化药物治疗:系统综述与网络Meta分析
尼达尼布、吡非尼酮和西地那非可能降低死亡风险(中等确定性)。尼达尼布、尼达尼布联合西地那非、吡非尼酮、pamrevlumab和pentraxin可能减缓FVC下降(中等确定性)。仅西地那非可能减少急性加重和住院(中等确定性)。
要点
- 尼达尼布、吡非尼酮和西地那非可能降低IPF患者死亡风险(中等确定性)。
- 尼达尼布、尼达尼布联合西地那非、吡非尼酮、pamrevlumab和pentraxin可能减缓FVC下降(中等确定性)。
- 仅西地那非可能减少急性加重和住院(中等确定性);激素联合硫唑嘌呤和乙酰半胱氨酸增加严重不良事件风险(高确定性)。
核心结论
- 尼达尼布、吡非尼酮和西地那非可能降低IPF患者死亡风险,仅西地那非可能减少急性加重和住院。
- 未来指南应考虑西地那非用于IPF,pamrevlumab和pentraxin等有前景药物需待3期试验完成后进一步研究。
研究设计与样本
- 系统综述与网络Meta分析,检索MEDLINE、EMBASE、Cochrane CENTRAL和clinicaltrials.gov从建库至2021年4月2日。
- 采用GRADE方法评估网络Meta分析证据确定性,计算合并相对危险度(RR)及95%可信区间(95%CI)。
主要发现
- 尼达尼布降低死亡风险RR 0.69(0.44至1.1),吡非尼酮RR 0.63(0.37至1.09;直接估计),西地那非RR 0.44(0.16至1.09),均为中等确定性。
- 尼达尼布减缓FVC下降2.92%(1.51至4.14),尼达尼布联合西地那非157 mL(-88.35至411.12),吡非尼酮2.47%(-0.1至5),pamrevlumab 4.3%(0.5至8.1),pentraxin 2.74%(1至4.83),均为中等确定性。
- 仅西地那非可能减少急性加重和住院(中等确定性)。
- 激素联合硫唑嘌呤和乙酰半胱氨酸与安慰剂相比增加严重不良事件风险(高确定性)。
关键数值与推荐
- 尼达尼布降低死亡风险RR 0.69(0.44至1.1),中等确定性。
- 吡非尼酮降低死亡风险RR 0.63(0.37至1.09;直接估计),中等确定性。
- 西地那非降低死亡风险RR 0.44(0.16至1.09),中等确定性。
- 尼达尼布减缓FVC下降2.92%(1.51至4.14),中等确定性。
- 激素联合硫唑嘌呤和乙酰半胱氨酸增加严重不良事件风险,高确定性。
临床怎么用
- IPF治疗决策时可参考尼达尼布、吡非尼酮和西地那非降低死亡风险的证据(中等确定性)。
- 西地那非可能减少急性加重和住院,未来指南应考虑其用于IPF。
- 避免使用激素联合硫唑嘌呤和乙酰半胱氨酸方案,因其增加严重不良事件风险(高确定性)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor prognosis. Our objective is to assess the comparative effectiveness of 22 approved or studied IPF drug treatments. METHODS: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and clinicaltrials.gov from inception to 2 April 2021. We included randomised controlled trials (RCTs) for adult patients with IPF receiving one or more of 22 drug treatments. Pairs of reviewers independently identified randomised trials that compared one or more of the target medical treatments in patients with IPF. We assessed the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach for network meta-analysis. We calculated pooled relative risk (RR) ratios and presented direct or network estimates with 95% credibility intervals (95% CI), within the GRADE framework. RESULTS: We identified 48 (10 326 patients) eligible studies for analysis. Nintedanib [RR 0.69 (0.44 to 1.1), pirfenidone [RR 0.63 (0.37 to 1.09); direct estimate), and sildenafil [RR (0.44 (0.16 to 1.09)] probably reduce mortality (all moderate certainty). Nintedanib (2.92% (1.51 to 4.14)), nintedanib+sildenafil (157 mL (-88.35 to 411.12)), pirfenidone (2.47% (-0.1 to 5)), pamrevlumab (4.3% (0.5 to 8.1)) and pentraxin (2.74% (1 to 4.83)) probably reduce decline of overall forced vital capacity (all moderate certainty). Only sildenafil probably reduces acute exacerbation and hospitalisations (moderate certainty). Corticosteroids+azathioprine+N-acetylcysteine increased risk of serious adverse events versus placebo (high certainty). CONCLUSION AND RELEVANCE: Future guidelines should consider sildenafil for IPF and further research needs to be done on promising IPF treatments such as pamrevlumab and pentraxin as phase 3 trials are completed.
引用
- Pitre T, Mah J, Helmeczi W, et al. Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Thorax. 2022. PMID: 35145039. doi:10.1136/thoraxjnl-2021-217976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。